This HTML5 document contains 72 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n12http://linked.opendata.cz/resource/AHFS/
n19http://linked.opendata.cz/resource/drugbank/drug/DB01058/identifier/chemspider/
n28http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n13http://linked.opendata.cz/resource/drugbank/dosage/
n5http://linked.opendata.cz/resource/drugbank/mixture/
n17http://bio2rdf.org/drugbank:
n9http://linked.opendata.cz/resource/drugbank/drug/DB01058/identifier/wikipedia/
n10http://linked.opendata.cz/resource/drugbank/drug/DB01058/identifier/pharmgkb/
admshttp://www.w3.org/ns/adms#
n25http://linked.opendata.cz/resource/drugbank/drug/DB01058/identifier/kegg-compound/
n21http://linked.opendata.cz/resource/drugbank/drug/DB01058/identifier/pdb/
n29http://linked.opendata.cz/resource/drugbank/drug/DB01058/identifier/pubchem-compound/
n16http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n23http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n27http://linked.opendata.cz/resource/drugbank/drug/DB01058/identifier/pubchem-substance/
n3http://linked.opendata.cz/ontology/drugbank/
n14http://www.drugs.com/cdi/
n7http://www.rxlist.com/cgi/generic2/
n26http://linked.opendata.cz/resource/drugbank/drug/DB01058/identifier/kegg-drug/
n4http://linked.opendata.cz/resource/drugbank/property/
n18http://linked.opendata.cz/resource/drugbank/drug/DB01058/identifier/drugbank/
xsdhhttp://www.w3.org/2001/XMLSchema#
n20http://linked.opendata.cz/resource/drugbank/drug/DB01058/identifier/national-drug-code-directory/
n24http://linked.opendata.cz/resource/atc/
n11http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01058
rdf:type
n3:Drug
n3:description
An anthelmintic used in most schistosome and many cestode infestations. [PubChem]
n3:dosage
n13:271B5C1C-363D-11E5-9242-09173F13E4C5 n13:271B5C1D-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Doenhoff MJ, Cioli D, Utzinger J: Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr Opin Infect Dis. 2008 Dec;21(6):659-67. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18978535 # McManus DP, Loukas A: Current status of vaccines for schistosomiasis. Clin Microbiol Rev. 2008 Jan;21(1):225-42. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18202444
n3:group
approved
n3:halfLife
0.8-1.5 hours (in serum)
n3:indication
For the treatment of infections due to all species of schistosoma.
owl:sameAs
n16:DB01058 n17:DB01058
dcterms:title
Praziquantel
adms:identifier
n9:Praziquantel n10:PA164764583 n18:DB01058 n19:4722 n20:0085-1747-01 n21:PZQ n25:C07367 n26:D00471 n27:46507082 n29:4891
n3:mechanismOfAction
Praziquantel works by causing severe spasms and paralysis of the worms' muscles. This paralysis is accompanied - and probably caused - by a rapid Ca 2+ influx inside the schistosome. Morphological alterations are another early effect of praziquantel. These morphological alterations are accompanied by an increased exposure of schistosome antigens at the parasite surface. The worms are then either completely destroyed in the intestine or passed in the stool. An interesting quirk of praziquantel is that it is relatively ineffective against juvenile schistosomes. While initially effective, effectiveness against schistosomes decreases until it reaches a minimum at 3-4 weeks. Effectiveness then increases again until it is once again fully effective at 6-7 weeks. Glutathione S-transferase (GST), an essential detoxification enzyme in parasitic helminths, is a major vaccine target and a drug target against schistosomiasis. Schistosome calcium ion channels are currently the only known target of praziquantel.
n3:packager
n28:271B5C18-363D-11E5-9242-09173F13E4C5 n28:271B5C19-363D-11E5-9242-09173F13E4C5 n28:271B5C16-363D-11E5-9242-09173F13E4C5 n28:271B5C17-363D-11E5-9242-09173F13E4C5
n3:synonym
Biltricide
n11:hasAHFSCode
n12:08-08-00
n3:foodInteraction
Take with food. Grapefruit and grapefruit juice should be avoided throughout treatment. Grapefruit can increase serum levels of this product.
n3:mixture
n5:271B5C15-363D-11E5-9242-09173F13E4C5 n5:271B5C13-363D-11E5-9242-09173F13E4C5 n5:271B5C14-363D-11E5-9242-09173F13E4C5 n5:271B5C11-363D-11E5-9242-09173F13E4C5 n5:271B5C12-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
80 to 85%
foaf:page
n7:praziquantel.htm n14:praziquantel.html
n3:IUPAC-Name
n4:271B5C22-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5C28-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5C27-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5C24-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5C25-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5C26-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5C20-363D-11E5-9242-09173F13E4C5 n4:271B5C38-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5C21-363D-11E5-9242-09173F13E4C5 n4:271B5C1E-363D-11E5-9242-09173F13E4C5 n4:271B5C3A-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5C1F-363D-11E5-9242-09173F13E4C5
n11:hasATCCode
n24:P02BA01
n3:H-Bond-Acceptor-Count
n4:271B5C2E-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5C2F-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5C29-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5C2A-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5C2C-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5C2B-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5C2D-363D-11E5-9242-09173F13E4C5
n3:absorption
Rapidly absorbed (80%)
n3:casRegistryNumber
55268-74-1
n3:containedIn
n23:271B5C1B-363D-11E5-9242-09173F13E4C5 n23:271B5C1A-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B5C34-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5C36-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5C37-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B5C39-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5C33-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5C32-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5C35-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5C23-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5C30-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5C31-363D-11E5-9242-09173F13E4C5